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Abstract - Breast cancer is one of the most frequently 
diagnosed malignancies and a leading cause of 
cancer death in women. Great advances in the 
treatment of primary tumors have led to a significant 
increment in the overall survival rates, however 
recurrence and metastatic disease, the underlying 
cause of death, are still a medical challenge. Breast 
cancer is highly dependent on neovascularization to 
progress. In the last years several anti-angiogenic 
drugs have been developed and administered to 
patients in combination with chemotherapeutic 
drugs.  
Collected preclinical evidence has proposed the 
endocannabinoid system as a potential target in 
cancer. The endocannabinoid anandamide has been 
reported to affect breast cancer growth at multiple 
levels, by inhibiting proliferation, migration and 
invasiveness in vitro and in vivo and by directly 
inhibiting angiogenesis. Aim of the present work is 
to investigate if anandamide is able to affect the pro-
angiogenic phenotype of the highly invasive and 
metastatic breast cancer cells MDA-MB-231. We 
found that following anandamide treatment, MDA-
MB-231 cells lose their ability to stimulate 
endothelial cells proliferation in vitro, due to a 
significant inhibition of all the pro-angiogenic 
factors produced by these cells. This finding adds 
another piece of evidence to the anti-tumor efficacy 
of anandamide in breast cancer. 
 





Breast cancer is the most common malignancy in women, 
excluding skin cancer, and is the second for mortality 
following lung cancer [1]. Great improvements in a 
comprehensive treatment for breast cancer have led to a 
significant increment in the overall survival rates, 
however recurrence and metastatic disease still represent 
an urgent medical problem. A huge amount of studies 
have demonstrated that breast cancer, like many solid 
tumors, depends on vascular growth to progress. Indeed, 
breast tumor angiogenesis is considered as an independent 
prognostic factor for breast cancer [2]. Several currently 
used conventional therapeutic regimens, such as numerous 
chemotherapeutic agents and endocrine therapies, show an 
intrinsic anti-angiogenic efficacy. Moreover, specific 
drugs that target angiogenesis have been developed. 
Among these, the most famous is the VEGF-neutralizing 
monoclonal antibody bevacizumab [3]. Unfortunately, 
numerous clinical trials conducted in breast cancer have 
revealed that this malignancy is modestly sensitive to 
bevacizumab, even when combined with standard 
chemotherapy protocols, showing a lack of survival 
advantage. These disappointing results led to recently 
discontinue its FDA approval in breast cancer treatment 
[4]. 
The endocannabinoid system, whose complex biological 
regulatory functions have been disclosed as crucial 
especially in several patho-physiological conditions, is 
emerging as a potential new target in cancer, due to the 
numerous evidence collected also in preclinical studies 
[5]. Natural and synthetic cannabinoids and compounds 
belonging to the endocannabinoid system (lipid molecules 
containing long-chain polyunsaturated fatty acids, amides, 
esters and ethers, like anandamide and 2-
arachidonoylglycerol (2-AG)), have been reported to 
affect tumor growth at more than one step in several types 
of malignancies. Indeed, they have been shown to inhibit 
cell proliferation and induce cell death, mainly through 
apoptosis and autophagy, but also to prevent tumor 
progression, metastasis formation and to inhibit oxygen 
and nutrient supply through a direct effect on tumor 
neovascularization [5]. As regard to breast cancer, CB1 
and CB2 receptors expression was found in several breast 
cancer cell lines with peculiar oncogenic patterns and 
different metastatic potential, as well as in human breast 
tumor tissues [6,7]. Cannabinoids and endocannabinoids-
related compounds were able to affect breast cancer cell 
proliferation, inducing apoptosis, and to inhibit migration 
and invasiveness [8-11]. The metabolically stable 
analogue of anandamide, Met-F-AEA, was reported to 
inhibit the proliferation of the estrogen receptor negative 
(ER-) MDA-MB-231 breast cancer cells, inducing a S 
phase cell cycle arrest correlated with DNA damage and 
Chk1 activation [12,13]. Anandamide inhibited also 
HMG-CoA reductase activity, thus affecting the pattern of 
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expression of oncogenic prenylated proteins involved in 
the proliferation and metastatic potential of breast cancer 
cells, such as Ras and RhoA [14]. Indeed, anandamide 
was able to reduce the invasiveness of highly metastatic 
MDA-MB-231 cells, inhibiting their migration through 
the RhoA signalling pathway [12, 15]. The efficacy of 
anandamide was maintained in the in vivo setting, since it 
was able to reduce the number and dimension of 
metastatic nodes in a mouse model of metastatic spreading 
[12]. Interestingly, we previously demonstrated that 
anandamide also directly affects angiogenesis, inhibiting 
endothelial cell proliferation, tube formation and 
neovascularization in vivo [16]. Aim of this study is to 
investigate if anandamide is able to affect the pro-
angiogenic phenotype of breast cancer cells, adding 




Cell lines. The human breast cancer cell line MDA-MB-
231was from Interlab cell line collection (IST, Genova) 
and was grown in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum. 
Human umbilical endothelial cells (HUVEC) were 
isolated from umbilical cords, as described [17] and 
grown in M199 medium supplemented with 10% fetal 
bovine serum, aFGF, bFGF, EGF, hydrocortisone and 
heparin. Cells were cultured at 37°C in a humidified 5% 
CO2 atmosphere. 
Drugs. Met-F-AEA (2-methyl-2’-F-anandamide), a 
metabolically stable analogue of anandamide, was 
purchased from Sigma-Aldrich. Met-F-AEA is indicated 
in the text as anandamide (AEA). 
Proliferation assay. Cell proliferation was evaluated, in 
vitro, by measuring [
3
H]-thymidine incorporation. In brief, 
5x10
3
 cells/ml were seeded into 96-well plates, 
immediately treated with the drugs, incubated for 24 h at 
37°C (5% CO2), then pulsed with 0.5 μCi/well of [
3
H]-
thymidine (Amersham Biosciences Europe, Italy) and 
harvested 4 h later. Radioactivity was measured in a 
scintillation counter (Wallac, Turku, Finland). 
Human angiogenesis array. Human angiogenesis antibody 
array on MDA-MB-231 tumor-conditioned medium was 
performed following manufacturer’s instructions 
(RayBiotech, Inc.). Culture supernatants corresponding to 
the final 24 h of incubation with anandamide (10 µM) 
were collected and assayed for angiogenic factors 
production. The array membranes were incubated with 
tumor-conditioned medium, stained using a 
chemiluminescence system (ECL-Amersham Biosciences) 
and then exposed to X-ray films (Kodak). Immunoreactive 
spots were quantified using Quantity One 1-D analysis 
software (Bio-Rad). 
Statistical analysis. Statistical computations were done 
using the GraphPad prism 6.0 software (San Diego, CA, 
USA). Data obtained from multiple experiments were 
calculated as mean±SD and analysed for statistical 
significance using Student’s T test or 1-way ANOVA for 
independent groups, with Tukey correction for multiple 





In order to evaluate the effect of anandamide on breast 
cancer-induced angiogenesis, we performed a simple in 
vitro angiogenesis assay using as angiogenic stimulus the 
tumor-conditioned medium (TCM) derived from MDA-
MB-231 cells. Briefly, MDA-MB-231 cells were treated 
with anandamide (10 μM, 24 h) and then the TCM was 
collected and tested on human umbilical vein endothelial 
cells (HUVEC) proliferation by [
3
H]-thymidine 
incorporation into DNA. As expected, TCM significantly 
induced endothelial basal proliferation vs control. 
Interestingly, we found that in the presence of TCM from 
anandamide-treated MDA-MB-231 cells, the proliferation 
of endothelial cells was strongly reduced (Fig. 1). 
This could be the result of an anandamide-switched 
balance between pro-angiogenic and anti-angiogenic 
factors produced by breast cancer cells in behalf of 
angiogenesis inhibitors. The next step was indeed to 
investigate the nature and levels of angiogenic molecules 
present in breast cancer TCM and their modulation after 
anandamide treatment. To this end we used an 
angiogenesis protein array. We found that, for all tested 
pro-angiogenic factors, there was a reduction trend 
following anandamide treatment (Table 1). 
In particular, IFNγ, leptin, TGFβ1, TIMP1, TIMP2, 
thrombopoietin and VEGF levels were significantly 
inhibited by anandamide in the conditioned medium of 





Fig. 1. Tumor conditioned medium from anandamide-treated MDA-
MB-231 inhibits angiogenesis. 
The graph reports the [3H]-thymidine incorporation levels (counts per 
minute) in endothelial cells expressed as mean ± SD values of three 





In the present work we demonstrated for the first time that 
a metabolically stable anandamide analogue, Met-F-AEA, 
already known to have an interesting anti-tumor efficacy 
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TABLE 1 
ANGIOGENIC FACTORS SECRETED BY MDA-MB-231 BREAST CANCER 









 %  
 
Angiogenin  20 ± 0.8  19.3 ± 2.3  5% 
ENA-78  3.8 ± 1.4  2.7 ± 1.5  29% 
bFGF  10.2 ± 2  9.8 ± 3.3  4% 
GRO  12.5 ± 0.1  10.7 ± 1.5  15% 
IFNγ  1.4 ± 0.07  1.1 ± 0.08**  21% 
IL6  18 ± 0.5  14.9 ± 4.6  17% 
Leptin  2.2 ± 0.2  0.9±0.07***  58% 
MCP-1  57.1 ± 6.0  49.4 ± 9.5  13% 
PDGF-BB  9.7 ± 1.9  6.8 ± 1.1  29% 
PlGF  10.5 ± 1.8  8.3 ± 1.2  21% 
RANTES  8.6 ± 0.1  7.9 ± 0.5  7% 
TGFβ1  35.2 ± 3.7  26.7 ± 1.8*  23% 
TIMP1  37.1 ± 2.6  30.2 ± 1.8*  18% 
TIMP2  75.7 ± 10.7  50 ± 2.8*  33% 
Thrombopoietin  10.5 ± 1.3  6.8 ± 0.6*  35% 
VEGF  42.6 ± 7.6  22.4 ± 3.2*  47% 
VEGF-D  10.6 ± 2.3  6.8 ± 1.9  36% 
Data are presented as mean ± SD of three experiments. % = percentage 
of inhibition vs TCM., * P <0.05, **P < 0.01, ***P < 0.001; Student’s T 
test. 
 
in several tumor types including breast cancer [12-15], 
along with a direct anti-angiogenic activity on endothelial 
cells [16], was able to affect the pro-angiogenic phenotype 
of the highly metastatic MDA-MB-231 breast cancer 
cells. Indeed, following anandamide treatment, MDA-
MB-231 cells lost the capability to stimulate endothelial 
cells proliferation in vitro, due to a significant inhibition 
of all the pro-angiogenic factors produced by tumor cells 
and usually responsible of their highly pro-angiogenic 
phenotype, allowing tumor cells to get nourish and thus to 
growth [18]. 
Our data (Fig. 1 and Table 1) show that the conditioned 
medium from breast cancer cells contains an amount of 
potent angiogenic factors and pro-inflammatory cytokines, 
as detected by an angiogenesis array.  
Among the factors secreted in large amounts in the tumor 
conditioned medium and deeply inhibited after treatment 
with anandamide in comparison to the control, there is 
VEGF (47% of inhibition vs control). VEGF is one of the 
major promoters of angiogenesis, through the binding to 
its tyrosine kinase receptors EGFR-1/Flt-1 and VEGFR-
2/KDR/Flk-1 it is able to regulate more than one step in 
angiogenesis, from endothelial cell survival and 
proliferation, to migration and vascular permeability [19]. 
As a critical factor in the induction of angiogenesis, 
VEGF has become an attractive target for the 
development of anti-angiogenic drugs, the most famous of 
whose is the VEGF-neutralizing monoclonal antibody 
bevacizumab [3]. Several solid cancers, such as colon and 
lung cancer, have been successfully treated with 
bevacizumab, whereas its approval in breast cancer has 
been recently revoked [20]. Indeed, despite the success of 
bevacizumab and other anti-angiogenic drugs, it has to be 
taken into account that even in responsive patients, anti-
angiogenic drugs generally prolong survival only in the 
order of few months and the clinical outcome is associated 
with the development of resistance and an increased risk 
of invasion and metastasis [2]. This could be due to the 
high redundancy of angiogenic molecules that tumors can 
produce to provide oxygen and nutrients stimulating their 
own growth and vascularization. Moreover, tumors can 
also switch between different types of vascularization that 
don’t necessarily require VEGF and its signalling. 
Therefore, strategies aimed to target angiogenesis at 
multiple levels could improve the efficacy and reduce the 
risk of resistance development. Interestingly, we found 
that anandamide is able to inhibit multiple angiogenic 
molecules beyond VEGF, thus significantly affecting the 
pro-angiogenic phenotype of breast cancer cells. 
In our study, we reported a significant reduction in the 
levels of the adipocytokine leptin, that has been reported 
to stimulate mammary tumor growth. Furthermore high 
levels of leptin in women correlate to an increased risk of 
breast cancer, metastatic tumor phenotype and poor 
prognosis [21,22]. Leptin stimulates angiogenesis and 
breast cancer invasiveness through the enhanced 
neovascularization, so it is a key factor to control breast 
cancer progression [23]. 
Noteworthy, most of the other growth factors and 
chemokines inhibited by anandamide treatment (IL8, 
GRO, ENA-78) have been reported to play a significant 
role in mediating neovascularization during tumorigenesis 
in several tumor types and have been shown to be of great 
importance in tumor progression [18]. These chemokines 
are under the regulation of PPARγ pathway and PPARγ 
ligands have been shown to inhibit tumor-associated 
angiogenesis by blocking the production of ELR+CXC 
chemokines [24]. It has been reported that anandamide 
induces transcriptional activation of PPARγ, binding 
directly to PPAR-ligand binding domain [25,26]. 
Therefore this could be the mechanism by which 
anandamide is able to inhibit the production of these 
angiogenesis-stimulating molecules, thus inhibiting breast 
cancer neovascularization.  
 
 
Translational Medicine @ UniSa - ISSN 2239-9747 2014, 10(3): 8-12 
 
11 
Università degli Studi di Salerno 
V. CONCLUSION 
 
In conclusion, our study adds another piece of evidence to 
the anti-tumor efficacy of the endocannabinoid 
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